Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019
February 25 2020 - 6:00AM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular
medicines for inflammatory diseases, will host an analyst call to
discuss the financial results for the first half FY 2020 ended
December 31, 2019. The webcast will begin at 4.30pm EST Wednesday,
February 26; 8.30am AEDT Thursday, February 27, 2020.
The live webcast can be accessed via
https://webcasting.boardroom.media/broadcast/5e4cd45be3e4a00857dbf7d4
To access the call only, dial 1 855 881 1339 (U.S.), 1800 870
643 or 1800 809 971 (Australia) or +61 2 9007 3187 (outside of the
U.S. and Australia). The conference identification code is
10004384.
The archived webcast will be available on the Investor page of
www.mesoblast.com
About MesoblastMesoblast Limited (Nasdaq: MESO;
ASX: MSB) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary mesenchymal lineage cell therapy technology platforms
to establish a broad portfolio of commercial products and
late-stage product candidates. Mesoblast’s proprietary
manufacturing process yields industrial-scale, cryopreserved,
off-the-shelf, cellular medicines. These cell therapies, with
defined pharmaceutical release criteria, are planned to be readily
available to patients worldwide.
Mesoblast has filed a Biologics License Application to the
United States Food and Drug Administration (FDA) to seek approval
of its product candidate Ryoncil™ (remestemcel-L) for
steroid-refractory acute graft versus host disease (acute GvHD).
Remestemcel-L is also being developed for other rare diseases.
Mesoblast is completing Phase 3 trials for its rexlemestrocel
product candidates for advanced heart failure and chronic low back
pain. If approved, RYONCIL is expected to be launched in the United
States in 2020 for pediatric steroid-refractory acute GVHD. Two
products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and
Singapore and is listed on the Australian Securities Exchange (MSB)
and on the Nasdaq (MESO). For more information, please see
www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter:
@Mesoblast
For further
information, please contact: |
|
Julie MeldrumCorporate CommunicationsT: +61 3 9639
6036E: julie.meldrum@mesoblast.com |
Schond GreenwayInvestor RelationsT: +1 212 880
2060E: schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2024 to Jun 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2023 to Jun 2024